Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)

Science Bulletin ◽

10.1016/j.scib.2021.03.019 ◽

2021 ◽

Author(s):

Linong Ji ◽

Weihong Song ◽

Hui Fang ◽

Wei Li ◽

Jianlin Geng ◽

...

Keyword(s):

Type 2 Diabetes ◽

Peroxisome Proliferator ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Double Blind Placebo

Download Full-text

Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3437798 ◽

2019 ◽

Author(s):

Linong Ji ◽

Weihong Song ◽

Hui Fang ◽

Wei Li ◽

Jianlin Geng ◽

...

Keyword(s):

Type 2 Diabetes ◽

Peroxisome Proliferator ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Double Blind Placebo ◽

Superiority Trial

Download Full-text

Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong

Journal of Diabetes ◽

10.1111/1753-0407.12425 ◽

2016 ◽

Vol 9 (4) ◽

pp. 386-395 ◽

Cited By ~ 10

Author(s):

Changyu Pan ◽

Ping Han ◽

Qiuhe Ji ◽

Chengjiang Li ◽

Juming Lu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Hong Kong ◽

Mainland China ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Abstract #866: Glycemic Efficacy and Tolerability of Muraglitazar, a Novel Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, in Drug-Naïve Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Endocrine Practice ◽

10.1016/s1530-891x(20)43695-x ◽

2005 ◽

Vol 11 ◽

pp. 27

Author(s):

Robert Frederich ◽

Kalyanee Viraswami-Appanna ◽

Cindy J. Rubin

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Peroxisome Proliferator ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Double Blind Placebo ◽

Receptor Alpha ◽

Drug Naïve

Download Full-text

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Endocrinology Diabetes & Metabolism ◽

10.1002/edm2.222 ◽

2021 ◽

Author(s):

Linong Ji ◽

Ling Li ◽

Jianhua Ma ◽

Xuefeng Li ◽

Dongmei Li ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chinese Patients ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes ( TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐week open‐label extension period

Diabetes Obesity and Metabolism ◽

10.1111/dom.14642 ◽

2022 ◽

Author(s):

Caroline Reilhac ◽

Julie Dubourg ◽

Carole Thang ◽

Jean‐Marie Grouin ◽

Pascale Fouqueray ◽

...

Keyword(s):

Type 2 Diabetes ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension ◽

Extension Period

Download Full-text

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study

Current Medical Research and Opinion ◽

10.1185/03007995.2014.912983 ◽

2014 ◽

Vol 30 (7) ◽

pp. 1245-1255 ◽

Cited By ~ 64

Author(s):

Yutaka Seino ◽

Takashi Sasaki ◽

Atsushi Fukatsu ◽

Michito Ubukata ◽

Soichi Sakai ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Abstract #860: Glycemic Efficacy and Safety of Muraglitazar, a Novel Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, in Patients with Type 2 Diabetes: Results of a Double-Blind, Randomized, Parallel-Group, Dose-Comparison Study

Endocrine Practice ◽

10.1016/s1530-891x(20)43690-0 ◽

2005 ◽

Vol 11 ◽

pp. 24-25

Author(s):

Cindy J. Rubin ◽

Kalyanee Viraswami-Appanna ◽

Fred T. Fiedorek

Keyword(s):

Type 2 Diabetes ◽

Peroxisome Proliferator ◽

Comparison Study ◽

Efficacy And Safety ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Receptor Alpha ◽

Dose Comparison ◽

Parallel Group

Download Full-text

17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

Diabetes ◽

10.2337/db19-17-or ◽

2019 ◽

Vol 68 (Supplement 1) ◽

pp. 17-OR ◽

Cited By ~ 1

Author(s):

LINONG JI ◽

WEIHONG SONG ◽

HUI FANG ◽

WEI LI ◽

JIANLIN GENG ◽

...

Keyword(s):

Type 2 Diabetes ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Superiority Trial

Download Full-text

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/review2 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text